mTOR Inhibitors for Aging

This trial explores whether mTOR inhibitors, specifically Everolimus and Sirolimus, can slow aging and prevent chronic diseases associated with aging. The goal is to understand how these medications work in the body and their potential to improve the health of older adults. Participants will receive varying doses of these drugs to assess their effects. Individuals aged 65 or older, who live independently and can understand trial procedures, might be suitable candidates. As a Phase 1 and Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group.

The trial requires that you do not take medications that increase or decrease sirolimus blood concentrations. If you are on such medications, you may need to stop them to participate.

Research has shown that sirolimus, a type of medication, is generally safe for healthy people. Although no serious side effects were reported, some individuals experienced more infections. This suggests that while sirolimus is usually well-tolerated, it might increase the likelihood of infections in some people.

Everolimus, a similar medication, is also considered safe. One study found it safe for older adults when used for six weeks. However, a longer study reported two deaths related to the treatment, indicating that while it is often safe, serious risks can occur with long-term use.

Researchers are excited about mTOR inhibitors like Everolimus and Sirolimus because they have the potential to target aging at the cellular level. Unlike standard treatments that may focus on symptoms or isolated age-related conditions, these drugs work by inhibiting the mTOR pathway, which is directly involved in cell growth and metabolism. This unique mechanism of action could slow down the aging process itself, offering a more holistic approach to enhancing longevity and healthspan. Additionally, both Everolimus and Sirolimus are being tested at different dosages, which might provide insights into optimizing their effectiveness and safety for anti-aging benefits.

Research suggests that drugs like sirolimus and everolimus, both studied in this trial, might help slow aging. Sirolimus has reduced signs of aging in cells, but limited data exists on its effects in people. Everolimus is generally safe for older adults and might aid aging by blocking certain cellular processes. Although more studies on human aging are needed, both treatments show promise by targeting mechanisms related to aging. Researchers are exploring these treatments for their potential to extend a healthy lifespan.¹⁶⁷⁸⁹